Genzyme's Cerdelga success bodes well for Fabry prospect

Cerdelga--Courtesy of Genzyme

Sanofi's ($SNY) Genzyme is testing an oral drug for Fabry disease, which would go up against its own Fabrazyme if and when it wins approval. But the company knows a thing or two about bringing new pills to market while keeping sales of older drugs intact. Last summer, it launched Gaucher treatment Cerdelga, which joined its infusion therapy, Cerezyme, on the market. And as Genzyme's head of rare diseases, Dr. Richard Peters, told the Boston Business Journal, of Cerdelga's patients, less than 40% have switched over from Cerezyme--meaning most of the pill's pool is completely new to Genzyme's lineup. More from FiercePharmaMarketing